Dr. Danielle M. Feigenbaum, M.D.
Neurology (Neurology Physician)
1520 San Pablo Street, Suite 3000
Los Angeles, CA 90033
Who else practices at this address →
Los Angeles County includes primary care (7% of residents) and mental health (13% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 15
- In the NPI registry since
- 2012
- Medicare patients seen, 2024
- 188
Licensed in California since 2012, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2012Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
CA license A123652 (first issued 2012; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Keck Hospital of Usc Los Angeles, CA
- Usc Verdugo Hills Hospital Glendale, CA
Medical groups
- Usc Care Medical Group Inc (1,380 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 188
- Services billed
- 763
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 239 | 128 |
| Established patient office or other outpatient visit, 40-54 minutes | 93 | 63 |
| Needle measurement of electrical activity in muscle with injection of chemical for paralysis of nerve muscle | 25 | 11 |
| Established patient office or other outpatient visit, 20-29 minutes | 22 | 17 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Carbidopa-Levodopa (carbidopa/levodopa) Other prescribers in Los Angeles, CA | 345 |
| Carbidopa-Levodopa Er (carbidopa/levodopa) Other prescribers in Los Angeles, CA | 216 |
| Rasagiline Mesylate | 98 |
| Donepezil Hcl Other prescribers in Los Angeles, CA | 92 |
| Rytary (carbidopa/levodopa) Other prescribers in Los Angeles, CA | 75 |
| Clozapine Other prescribers in Los Angeles, CA | 57 |
| Propranolol Hcl Other prescribers in Los Angeles, CA | 50 |
| Pramipexole Dihydrochloride (pramipexole di-hcl) Other prescribers in Los Angeles, CA | 49 |
| Gabapentin Other prescribers in Los Angeles, CA | 49 |
| Primidone Other prescribers in Los Angeles, CA | 40 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $24.82 in total to this clinician.
| Pfizer Inc. | $24.82 |
|---|
| Food and Beverage | $24.82 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $24,420 in research payments for these studies, mostly to the institutions running them.
- A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of UCB0022 in Study Participants With Advanced Parkinson's Disease
UCB SA · Completed · NCT06055985
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.